Wildcat Capital Management, LLC Allogene Therapeutics, Inc. Transaction History
Wildcat Capital Management, LLC
- $252 Million
- Q4 2024
A detailed history of Wildcat Capital Management, LLC transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Wildcat Capital Management, LLC holds 2,920,787 shares of ALLO stock, worth $4.32 Million. This represents 2.46% of its overall portfolio holdings.
Number of Shares
2,920,787
Previous 2,920,787
-0.0%
Holding current value
$4.32 Million
Previous $8.18 Million
23.93%
% of portfolio
2.46%
Previous 4.0%
Shares
10 transactions
Others Institutions Holding ALLO
# of Institutions
166Shares Held
133MCall Options Held
59.4KPut Options Held
113K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$27.7 Million1.25% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$24.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.33MShares$12.3 Million0.0% of portfolio
-
State Street Corp Boston, MA7.01MShares$10.4 Million0.0% of portfolio
-
Capital World Investors Los Angeles, CA6.9MShares$10.2 Million0.0% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $213M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...